Stock Track | Mind Medicine (MindMed) Soars 6.61% Pre-market on Oppenheimer's Outperform Rating and $25 Price Target

Stock Track

Aug 04, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares surged 6.61% in pre-market trading on Monday, as investors reacted positively to a new analyst rating from Oppenheimer.

Oppenheimer initiated coverage on Mind Medicine with an Outperform rating and set a price target of $25. This bullish stance aligns with the overall sentiment among analysts polled by FactSet, who have given the company an average rating of "buy" with a mean price target of $25.

The significant price target, which represents a substantial upside from the stock's current trading levels, appears to be driving investor enthusiasm. As Mind Medicine continues to advance its research and development in psychedelic-inspired medicines, this positive analyst coverage could potentially attract more investor attention to the company's growth prospects in the emerging field of psychedelic therapeutics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1110572160"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110572160\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110572160?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110572160","market":"nz","top_or_hot":-1,"title":"Stock Track | Mind Medicine (MindMed) Soars 6.61% Pre-market on Oppenheimer's Outperform Rating and $25 Price Target","media":"Stock Track","content":"<p>Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares surged 6.61% in pre-market trading on Monday, as investors reacted positively to a new analyst rating from Oppenheimer.</p>\n\n<p>Oppenheimer initiated coverage on Mind Medicine with an Outperform rating and set a price target of $25. This bullish stance aligns with the overall sentiment among analysts polled by FactSet, who have given the company an average rating of \"buy\" with a mean price target of $25.</p>\n\n<p>The significant price target, which represents a substantial upside from the stock's current trading levels, appears to be driving investor enthusiasm. As Mind Medicine continues to advance its research and development in psychedelic-inspired medicines, this positive analyst coverage could potentially attract more investor attention to the company's growth prospects in the emerging field of psychedelic therapeutics.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mind Medicine (MindMed) Soars 6.61% Pre-market on Oppenheimer's Outperform Rating and $25 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mind Medicine (MindMed) Soars 6.61% Pre-market on Oppenheimer's Outperform Rating and $25 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-04 21:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares surged 6.61% in pre-market trading on Monday, as investors reacted positively to a new analyst rating from Oppenheimer.</p>\n\n<p>Oppenheimer initiated coverage on Mind Medicine with an Outperform rating and set a price target of $25. This bullish stance aligns with the overall sentiment among analysts polled by FactSet, who have given the company an average rating of \"buy\" with a mean price target of $25.</p>\n\n<p>The significant price target, which represents a substantial upside from the stock's current trading levels, appears to be driving investor enthusiasm. As Mind Medicine continues to advance its research and development in psychedelic-inspired medicines, this positive analyst coverage could potentially attract more investor attention to the company's growth prospects in the emerging field of psychedelic therapeutics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1110572160","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110572160","pubTimestamp":1754315905,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares surged 6.61% in pre-market trading on Monday, as investors reacted positively to a new analyst rating from Oppenheimer.  Oppenheimer initiated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"个股追踪|Mind Medicine(MindMed)盘前大涨6.61%，奥本海默给予跑赢大盘评级，目标价25美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":1},"content_text":"Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares surged 6.61% in pre-market trading on Monday, as investors reacted positively to a new analyst rating from Oppenheimer.\nOppenheimer initiated coverage on Mind Medicine with an Outperform rating and set a price target of $25. This bullish stance aligns with the overall sentiment among analysts polled by FactSet, who have given the company an average rating of \"buy\" with a mean price target of $25.\nThe significant price target, which represents a substantial upside from the stock's current trading levels, appears to be driving investor enthusiasm. As Mind Medicine continues to advance its research and development in psychedelic-inspired medicines, this positive analyst coverage could potentially attract more investor attention to the company's growth prospects in the emerging field of psychedelic therapeutics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}